INNOGENETICS NV is an international biotechnology company that develops and markets diagnostic assays in the fields of Infectious Diseases, Genetic Testing, Transplantation, Neurodegeneration, and Oncology, with a special focus on molecular diagnostics and multi-parameter testing. Innogenetics was founded on July 18, 1985 by Erik Tambuyzer, Hugo Van Heuverswyn and Rudi Mariën. In 1992, the company launched the first commercial tests for cystic fibrosis in Europe (INNO-LiPA CFTR) and in 1993 the first commercial test for Hepatitis C virus (HCV) genotyping worldwide (INNO-LiPA HCV). In 1995, the first commercial Alzheimer's disease research test for hTau was launched (INNOTEST hTau Ag). In 1998, the company launched the first commercial Alzheimer's disease research test for β-Amyloid and in 2002 the first commercial test for Hepatitis B virus (HBV) genotyping (INNO-LiPA HBV Genotyping). In 2008, Innogenetics N.V. was acquired Solvay Pharmaceuticals and in 2010 by Fujirebio Inc. and changed name to Fujirebio Europe N.V. on October 1st 2013.